Article
Ledipasvir/Sofosbuvir Is Effective for Relapsed Genotype 1b Hepatitis C Virus Patients after Achieving a Sustained Virological Response at Post-treatment Week 12 with Glecaprevir/Pibrentasvir.
Internal medicine (Tokyo, Japan) - 1 Sept 2023
Manabe Takushi, Tadokoro Tomoko, Nakahara Mai, Ohura Kyoko, Fujita Koji, Tani Joji, Morishita Asahiro, Ogawa Chikara, Masaki Tsutomu
Abstract excerpt
A patient with genotype 1b chronic hepatitis C virus who had been treated with pegylated interferon and ribavirin (RBV) was treated with glecaprevir/pibrentasvir (GLE/PIB) for 12 weeks. A sustained virological response at post-treatment week 12 (SVR12) was achieved, but relapse occurred approximately 31 weeks after the end of treatment. The patient had a history of allergy to RBV and was treated with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.